Literatur

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis

In: Korean J. Intern. Med. 37, S. 949–957. DOI: 10.3904/kjim.2021.458.

Weitere Veröffentlichungen:

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis. A randomised trial.

Weitere Informationen

Escherichia coli Stamm Nissle 1917: Stärkung der intestinalen Barriere bei Alzheimer-Patienten – Ergebnisse einer klinischen Studie

Weitere Informationen

Potential benefit of probiotic E. coli Nissle in term neonates.

Weitere Informationen

Park, Soo-Kyung; Kang, Sang-Bum; Kim, SangSoo; Kim, Tae Oh; Cha, Jae Myung; Im, Jong Pil et al. (2022): Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.